Story

We are an award winning biotech company in the field of protein production. We’ve mastered and industrialized a process for protein expression like no other.

Our heritage is in the pharma space, an area with the highest requirements, including regulatory. Our portfolio has reached the approval and validation from the European Medicines Agency. We were awarded the “best company in Animal Health” award by IHS in 2021.

We now intend to apply the same rigorous methodology to alternative proteins for the food space. We intend to be the facilitator of smart protein by enabling the production of competitively priced growth factors at scale.

Sustainability

Sustainability is at our core.

Algenex’s expertise in the production of biologics is a catalyst for Good Health and Well Being.

We believe that alternative proteins will be part of the journey to address Global Hunger and Climate Change, will lead to Responsible Consumption and Production and help protect Life Below Water and Life on Land.

We will be a central part of this journey. Importantly, we facilitate an end-market which is sustainable with a platform leveraging nature at its fullest.

No bioreactors. Just nature. Simple yet effective.

Algenex is committed to contribute to the UN Sustainable Development Goals #2 Zero Hunger, #3 Good Health and Well-Being, #12 Responsible Consumption and Production, #13 Climate Action, #14 Life Below Water and #15 Life on Land Algenex is committed to contribute to the UN Sustainable Development Goals #2 Zero Hunger, #3 Good Health and Well-Being, #12 Responsible Consumption and Production, #13 Climate Action, #14 Life Below Water and #15 Life on Land

Management

Roberto Barzi, Algenex CEO

Roberto Barzi

CEO

+ More info
x

Roberto Barzi

CEO

Roberto Barzi is an investor in the healthcare sector, where he has been active for the past decade. Originally part of 3i’s global healthcare team, he later founded Fort Rock Capital, a specialist investor in the space. He is the Managing Partner of VitaTech (lifesciences), based in Luxembourg and active across Europe. He currently serves on the boards of Vasopharm GmbH (Germany, traumatic brain injury), GNS Healthcare (USA, AI and digital health) and Medinet (UK, clinical services).

José Escribano

José Escribano

Founder and CSO

+ More info
x

José Escribano

Founder and CSO

Jose is a specialist in viral infectious diseases and in the development of biotechnology applications of viruses, with more than 120 scientific contributions in international journals and numerous licensed patents. He is on the editorial board of several virology and biotechnology journals. José is a graduate and Ph.D from Complutense University of Madrid in Veterinary Medicine and carried out postdoctoral studies in different institutions of USA. Jose served as Research Professor in a Spanish scientific institution and has over 25 years of experience in science management. As entrepreneur, he is co-founder of ALGENEX and LogicBiology.

Virginia Gonzalez

Virginia González

CFO

+ More info
x

Virginia González

CFO

Virginia has more than 20 years’ experience in finance. She started her career in the finance department of Decathlon after completing her degree in Business Administration at the University of Oviedo, Spain. She later joined the biotechnology company TiGenix, a dual listed Company (Nasdaq & Euronext ) which was acquired by Takeda 2019. During her 13 years at TiGenx she held different roles of responsibility, including finance director and head of controlling and consolidation. Virginia holds a master in Business Administration from CEF and an Advance Management Program from Instituto de Empresa, Madrid.

Romy Dalton

Romy Dalton

COO

+ More info
x

Romy Dalton

COO

Romy has more than 17 years of experience on Molecular Biology and Virology and eleven scientific publications in peer reviewed journals. She has worked first as a researcher and then as a Project Leader at several Biotech Companies. She joined Algenex more than three years ago in the position of Chief Operations Officer and manages the Comercial Agreements, Human Resources, Patent Portfolio and supervises the scientific projects.

Strategic Advisory Board

Dr. René Aerts

Dr. René Aerts

Ex Merck Exec. with global responsability for Animal Health

+ More info
x

Dr. René Aerts

Ex Merck Exec. with global responsability for Animal Health

Dr. René Aerts is the Founder of RA-Consultancy BV and currently serves as Partner at NovioCap BV. He retired from Merck/MSD Animal Health in 2013 where he had been a member of the Executive Committee since 2008 as Global Head Vaccine Research. He previous held senior positions in Manufacturing Operations, Regulatory Affairs and R&D at Intervet International. He holds non-executive and Advisory Board positions at AGC Biologics (USA), The Jenner Institute (UK), ImmunoValley (NL), Schothorst Feed Research BV (NL) and Alternative Gene Expression Ltd (ES). Mr. Aerts received a PhD in Bioanalytics and Pharmacochemistry from the Free University of Amsterdam in 1990.

Dr. DamiĂ  Tormo

Dr. DamiĂ  Tormo

Founder and managing partner of Columbus Venture Partners

+ More info
x

Dr. DamiĂ  Tormo

Founder and managing partner of Columbus Venture Partners

Damià has been widely recognized for his capacity to combine a brilliant scientific career with that of an entrepreneur and investor. He received his PhD in immunology and molecular genetics from the Rheinische Friedrich-Wilhelms-Universität Bonn (Germany) and holds a Masters in international management of biotechnology from the IE Business School. During his scientific tenure he was actively engaged in R&D in and for institutions including University of Cambridge (UK), Michigan University (USA) and Centro Nacional de Investigaciones Oncológicas (CNIO) and authored publications in peer reviewed journals including Nature and Cancer Cell. As a founder and managing partner of Columbus Venture Partners, he has helped developed numerous biotechnology companies in Europe and the US, serving on the Board of Artax Biopharma, Viralgen Vector Core, Polypeptide Therapeutic Solutions, Bioncotech Therapeutics and Sanifit.

Jean Stéphenne

Jean Stéphenne

Ex member of the Corp. Exec. Team of GSK an CEO of GSK Biologicals (now GSK Vaccines)

+ More info
x

Jean Stéphenne

Ex member of the Corp. Exec. Team of GSK an CEO of GSK Biologicals (now GSK Vaccines)

Jean Stéphenne is a highly-experienced life sciences executive, who has served in senior leadership roles at a large number of biotechnology and pharmaceutical companies, most recently as Chairman of TiGenix (acquired by Takeda in 2019). Jean was previously a Member of the Corporate Executive Team of GlaxoSmithKline (GSK) and Chief Executive of GSK Biologicals (now GSK Vaccines). During his 40-year tenure, he grew a company of 50 people into a fully integrated worldwide leader in vaccine development, with 12,000 employees. He currently serves on the Board of various life sciences companies including Vaxxilon (DE), OncoDNA (BE), BoneTherapeutics (BE), CureVac (DE) and Bepharbel (BE) as well as in biotech investments funds Vesalius (BE) and Merieux Investments (FR). For his contribution to the Belgian economy and global public health, he has received diverse business recognitions and was honored with various titles by the Belgian and British governments.

Nicola Zambon

Nicola Zambon

Investor

+ More info
x

Nicola Zambon

Investor

Nicola Zambon has 23 years of M&A and principal investment experience. He is the founder and managing partner of Cleon Capital, an independent advisory and investment company with offices in Madrid and Milan. Prior to founding Cleon, he served as director and partner of the private equity firms Investindustrial and Ergon Capital. Nicola is a board member of 15 companies located in various jurisdictions across Europe.

Claudia Jimenez

Claudia Jiménez

Investor

+ More info
x

Claudia Jiménez

Investor

Claudia started her career in 1998 in Investment Banking, where she managed M&A projects across various industries for WestLB AG. After completing an international MBA at Instituto de Empresa in Spain, she joined Cellerix SA in 2006, where she contributed to the company’s growth through its series B and C financing rounds, its merger with TiGenix SA and the partnering of its lead asset with Takeda in a licensing deal worth up to €380M. Following the TiGenix’ Nasdaq IPO, Claudia became responsible for investor relations and communications until the Company’s acquisition by Takeda in 2018 in a deal worth >€500M.

From 2019 until Feb 2022 Claudia was the CEO of Algenex SL. Under her leadership, Algenex grew from a university - based R&D site to a GMP-grade CDMO with capacity to manufacture up to 100M vaccine doses per year, a first vaccine approved by EMA and UK regulators and signed commercial agreements with leading companies in the human and animal health space. Algenex was recognized as the best animal health company in Europe in 2021 by IHS (part of S&P global).

Julen Oyarzabal

Julen Oyarzabal

Partner at Columbus Venture

+ More info
x

Julen Oyarzabal

Partner at Columbus Venture

Dr. Julen Oyarzabal has spent more than 20 years working in the drug discovery and biopharmaceutical industry. He started his career as researcher at the University of California San Francisco (UCSF) and later he joined the University of Southampton. In 2001, Dr. Oyarzabal joined Johnson & Johnson Pharmaceutical R&D where he led several projects in the CNS therapeutic area. Five years later, he set up and led the Computational Medicinal Chemistry section at the Spanish National Cancer Research Center (CNIO). In 2010, Dr. Oyarzabal joined the Center for Applied Medical Research (CIMA), at the University of Navarra, to set up the small molecule discovery platform and led the Molecular Therapeutics Program. From 2013 to 2018 he was also director of Translational Sciences leading scouting activities, from the University Hospital and CIMA.

He is co-inventor of more than 25 patents and published more than 100 peer-reviewed scientific articles; he (co-)led publications in prestigious journals such as Nature Comm, Angew Chem, or J Med Chem. In addition, Dr. Oyarzabal is on the Board of Directors for the Academic Drug Discovery Consortium (ADDC) and, from 2012 to 2019, he was member of the European Medicines Agency (EMA). As partner of Columbus Venture Partners, he has served on the Board of Polypeptide Therapeutic Solutions.

Shareholders

Algenex is supported by a strong investor base, that includes institutional investors, venture capital funds, founders and the management team.